Oligometastatic bladder cancer, defined as a cancer with limited metastases, is a potential target for curative metastasis-directed therapy in a multidisciplinary framework. The consensus definition of oligometastatic bladder cancer is a valuable starting point for clinical trials, but challenges remain in accurately characterizing metastatic burden with current imaging modalities and determining optimal strategies to treat patients with lymph node involvement.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
EAU Guidelines. Edition presented at the EAU Annual Congress Amsterdam 2022 (EAU Guidelines Office, 2022).
Bamias, A. et al. Definition and diagnosis of oligometastatic bladder cancer: a delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur. Urol. https://doi.org/10.1016/j.eururo.2023.05.005 (2023).
Voskuilen, C. S. et al. Staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography changes treatment recommendation in invasive bladder cancer. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2021.01.005 (2022).
Mertens, L. S. & Horenblas, S. Bladder cancer: oligometastases and imaging. Nat. Rev. Urol. 14, 513–514 (2017).
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).
Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218–1230 (2020).
Heck, M. et al. Abstract LB07: long-term results from the randomized trial LEA: extended versus standard lymph node dissection in bladder cancer patients undergoing radical cystectomy. Presented at EAU23 (2023).
Lerner, S. P. et al. SWOG S1011: a phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. J. Clin. Oncol. 41 (Suppl. 16), 4508 (2023).
Zlotta, A. R. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet. Oncol. 24, 669–681 (2023).
Spaas, M. et al. Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.2132 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mertens, L.S., Psutka, S.P. & Mir, M.C. Bladder cancer oligometastases — definition and treatment. Nat Rev Urol 20, 701–702 (2023). https://doi.org/10.1038/s41585-023-00815-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-023-00815-1
